相关实验视频

Updated: Jul 1, 2025

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

预后因素与移植后环胺的平分异样移植治疗急性髓性白血病的预后因素

Sho Shibata¹, Yasuyuki Arai², Tadakazu Kondo³

¹Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

|March 11, 2024

概括

可以预测具有移植后循环胺 (PTCy) 结果的哈普罗同一性造血干细胞移植 (哈普罗-HCT). 一个评分系统确定了急性髓性白血病患者的有利,中间和不良预后组.

科学领域:

血液学血液学血液学
在瘤学瘤学.
移植医学移植医学

背景情况:

当HLA匹配的捐赠者无法获得时,哈普洛同一性造血干细胞移植 (haplo-HCT) 是一种可行的替代方案.
移植后循环胺 (PTCy) 已成为哈普罗-HCT的标准方法,证明了有效的移植对宿主疾病 (GVHD) 抑制和安全性.

研究的目的:

为了确定影响急性髓性白血病 (AML) 患者经历Haplo-HCT与PTCy的预后因素影响结果.
开发一个用于患者分层和结果评估的预测评分系统.

主要方法:

对366名AML患者的回顾性分析,这些患者在2010年至2019年期间接受了Haplo-HCT与PTCy.
多变量考克斯回归分析以确定与整体存活 (OS) 相关的独立预后因素.

主要成果:

接受者年龄较大 (≥60岁),男性捐赠者与男性接受者,CMV血清匹配 (D-/R+),细胞遗传风险差,移植时非CR状态,以及之前的HCT病史与更糟糕的生存状况有关.
一个评分系统将患者分为有利的 (0-1分),中间的 (2-3分) 和差的 (≥4分) 群体.
两年后的生存率分别为有利,中等和贫困群体的79.9%,49.2%和25.1% (P < 0.001).

结论:

在AML患者中确定了具有PTCy的Haplo-HCT显著预后因素.
一个新的评分系统可以预测结果,有助于患者管理和风险分层.

关键词:

在GVHD的预防中.急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.一致的血型造血干细胞移植.在移植后的循环胺胺.

更多相关视频

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...